Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - Novoteris

Drug Profile

Nitric oxide inhalation - Novoteris

Alternative Names: Thiolanox

Latest Information Update: 30 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novoteris
  • Developer Mallinckrodt Inc.; Nitric Solutions; Novoteris; University of British Columbia; University of Toronto
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Cystic fibrosis; Mycobacterial infections; Nontuberculous mycobacterium infections
  • No development reported Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 16 Jul 2021 Mallinckrodt in collaboration with Mallinckrodt terminates a phase II NONTM trial in Non-tuberculous mycobacterium infection and COVID-2019 infections, in Canada, due to low no. of COVID-2019 patients and funding(NCT03331445)
  • 09 Mar 2021 Phase-II development is ongoing in Mycobacterium infection (Treatment-experienced) in Canada (Inhalation) (NCT03473314)
  • 01 Apr 2020 Therapeutic Products Directorate of Health Canada approves IND application for Nitric oxide inhalation (Thiolanox) in COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top